×
Abstract P2-01-10: Circulating CAF/CTC complexes and breast cancer metastasis
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-01-10

May 11th, 2018 - Background: Metastatic disease in breast cancer (BC) is the leading cause of cancer-related mortality among women worldwide. Synergy between cancer cells and non-cancer cells of the tumor microenvironment (TME) are vital for disease progression. Cancer associated fibroblasts (CAFs) are the major cell type in the stroma of BC and are critical mediators of tumor progression and metastasis. Transp...

Abstract P1-17-02: Ado-trastuzumab emtansine (TDM-1) treatment and brain metastases in HER2 positive metastatic breast cancer patients: Final analysis of an italian multicenter study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-02

Oct 10th, 2018 - Background: Ado-trastuzumab emtansine (T-DM1) is a drug-antibody conjugate whose activity has been confirmed in HER2+ advanced breast cancer (BC) patients by the phase 3 EMILIA trial (Verma et al, NEJM 2012). Within the 991 patients enrolled in this trial, about 10% were affected with brain metastases (BM); in this subgroup, safety and efficacy of T-DM1 were confirmed although without any PFS i...

Abstract P1-17-03: Abemaciclib for the treatment of brain metastases secondary to hormone receptor positive breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-03

Oct 12th, 2018 - Background: Although a lower percentage of patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) develop brain metastases when compared with triple negative and HER2+ MBC patients, there are no regulatory approved systemic agents for the treatment of HR+ breast cancer brain metasteses, and this remains an unmet medical need. Standard local treatment options include surger...

Abstract P1-17-08: Efficacy of lapatinib and capecitabine combination therapy in brain metastases from HER-2 positive metastatic breast cancer: A systematic review and meta- analysis
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-08

Oct 13th, 2018 - Background: Brain metastases contribute to significant morbidity and mortality in breast cancer. Approximately one fourth of breast tumors overexpress the human epidermal growth factor receptor 2 (HER2) protein and are twice as likely to develop brain metastases. There are currently no systemic therapies approved. We undertook a systematic review and pooled analysis of trials to determine the e...

Abstract P6-03-04: Central nervous system miliary metastasis in breast cancer patients
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-03-04

May 23rd, 2018 - Background: Little is known regarding central nervous system (CNS) miliary metastasis (MiM), which was first described as “carcinomatous encephalitis” by Madow and Alpers in 1951. The majority of reported cases arise from primary lung and gastrointestinal adenocarcinomas, with occasional melanoma primaries and one reported case in breast cancer. Moreover, clinicopathologic correlates, disease o...

Abstract P6-04-02: CDK6 might be a key factor for efficacy of CDK4/6 inhibitor and the hormone sensitivity following acquired resistance
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-04-02

Jan 13th, 2019 - Background: CDK4/6 inhibitors have received FDA breakthrough therapy designation as 1st line treatment for advanced estrogen receptor positive breast cancer patients. However, the benefit offered by CDK4/6 inhibitors is individually different and furthermore acquired resistance to the drugs is monumental challenges. It is urgent need to search for the biomarker and understand the drug sensitivi...

Abstract P6-03-06: Assessing occult brain metastasis with CT scan or MRI in HER2-positive breast cancer patients at initial diagnosis
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-03-06

May 27th, 2018 - Patients (pts) with HER2-positive breast cancer (BC) have a high risk of developing brain metastases (BM) that might be due to longer survival, low diffusion of Trastuzumab (T) in the CNS or an unknown incidence of occult BM at diagnosis. In a series of metastatic BC, occult metastasis was found in 15 % of the patients and Her2 over expression was an independent risk factor 1.In a series of ear...

Abstract P6-04-01: Rapalog everolimus induces G1 cell cycle arrest through autophagy-mediated protein degradation of cyclin D1 in breast cancer cells
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-04-01

Jan 14th, 2019 - Rapamycin analogs (rapalogs) inhibit mammalian target of rapamycin (mTOR) and are known to cause induction of autophagy and G1 cell cycle arrest. However, it remains unknown whether rapalog-induced autophagy plays a critical role in its regulation of cell cycle. We, for the first time, found that rapalog everolimus could stimulate autophagy-mediated Cyclin D1 degradation in breast cancer cells....

Abstract P6-10-06: Racial differences in the characteristics and outcomes of young breast cancer patients: A national population-based study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-10-06

Jun 3rd, 2018 - Background: Disparity in demographic characteristics as it relates to breast cancer outcomes is well-studied. However, studies evaluating racial differences exclusively among young patients are more limited. We sought to examine socioeconomic and clinical factors and their impact on outcomes in young patients, as well as to determine whether variation in outcomes changed over the 22-year study ...

Abstract P6-05-04: mRNA expression of PTK6V1 and PTKV2 in human breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-05-04

Jan 15th, 2019 - BACKGROUND: Protein tyrosine kinase 6 (PTK6) is an intracellular protein that is upregulated in several human cancers and its localization to the plasma-membrane facilitates its various oncogenic roles in breast cancer cell proliferation, survival, and migration. The full length protein (PTK6V1) and alternative splice variant (PTK6V2) seem to play different roles with the latter being negative ...

Abstract P6-10-03: The association between type-2 diabetes and risk of mortality after invasive breast cancer among Hispanic and non-Hispanic white women from New Mexico
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-10-03

Jun 4th, 2018 - Background: Evidence suggests that the presence of Type-2 diabetes at the time of breast cancer diagnosis adversely affects survival independent of breast cancer stage, grade, and tumor phenotype. Few of these epidemiological studies have included Hispanic breast cancer survivors in whom diabetes and obesity are prevalent. Objective: We examined the association between self-reported diabetes hi...

Abstract P3-17-01: Geographic variation in adverse event reporting patterns in breast cancer clinical trials
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-17-01

Oct 17th, 2018 - Introduction: Adverse event (AE) reporting in clinical trials (CT) informs the safety of investigational products. Once approved, safety information in the monograph and prescribing information mainly derive from CT data. Some studies have shown geographic variations in the AE reporting patterns in multinational CT; none of them assessed this variation in cancer CT. We conducted a study to anal...

Abstract P4-06-08: An interlaboratory study of complex mutation detection in genes associated with hereditary breast and ovarian cancer highlights both successes and current challenges
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-06-08

Jun 11th, 2018 - Background: Established laboratory methods, including next-generation sequencing (NGS), can accurately and inexpensively detect certain classes of clinically important mutations in readily accessible protein coding regions of a patient's DNA. These events include single nucleotide variants (SNVs), small insertions/deletions (indels), and sometimes medium sized copy-number deletions or duplicati...

Abstract P1-08-05: A phase I trial of chemotherapy followed by infusions of activated T cells armed with anti-CD3 and anti-HER2 bispecific antibody for stage III, Her2+ or Her2- breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-08-05

Oct 18th, 2018 - Background: The balance in the immune system between immune surveillance and tolerance is known to be associated with the prognosis of breast cancer patients. The aim of this phase I study was to assess the safety of anti-CD3 x anti-HER2Bi bispecific antibody targeted (BAT) activated T cells (TC) in high risk breast cancer patients. The BAT T-cells exhibit anti-HER2 cytotoxicity, proliferate, a...

Abstract P4-06-11: Is myriad a reliable genetic risk model for prediction BRCA1/2 mutations in Romanian high-risk breast cancer patients?
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-06-11

Jun 16th, 2018 - Aim: To assess the predictive efficacies of genetic risk model Myriad for BRCA1/2 mutations in high-risk Romanian breast cancer patients (pts). Methods: This prospective study evaluated the validity of Myriad risk assessment model for 250 high-risk breast cancer pts tested for BRCA1/2 mutations between 02.2015-12.2016 at IOCN. Inclusion criteria selected pts diagnosed with triple negative breas...

Abstract P3-09-09: Assessing utility of breast cancer risk assessment tool in comparison to Tyrer-Cuzick model for determination of breast cancer risk and implications for chemoprevention
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-09-09

Jun 23rd, 2018 - Background Despite findings that the Tyrer-Cuzick (IBIS Breast Cancer Risk Evaluation Tool or TC) model is more predictive of breast cancer risk than the Gail model (NCI maintained Breast Cancer Risk Assessment Tool or BCRAT), BCRAT is commonly clinically used as per the United States Preventive Services Task Force (USPSTF), with a 5-year risk for breast cancer (BC) of greater than 3% on BCRAT,...

Abstract P4-14-01: Changes in treatment and improved survival of inflammatory breast cancer (IBC/T4d) and T4a-c lesions: 1990-2014
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-14-01

Oct 21st, 2018 - Background: T4 breast cancer (BC) is a tumor of any size with direct extension to the chest wall and/or to the skin. Tumor stage T4a-d including IBC (T4d) are aggressive cancers, often presenting with distant metastases or progressing quickly to metastatic breast cancer (MBC). Methods: We conducted a retrospective cohort analysis of invasive BC cases with T4 tumor stage from a prospectively col...

Abstract P3-09-06: Predicting cardiovascular versus cancer mortality in a cohort of breast cancer survivors
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-09-06

Jun 24th, 2018 - Background: Given improved survival after breast cancer diagnosis for women with non-metastatic disease, many will likely survive their disease and ultimately die from causes other than breast cancer, the most frequent being cardiovascular disease. There are numerous risk prediction models, such as the Framingham risk score, to identify persons who are at high risk for a cardiovascular event or...

Abstract P4-14-02: CSF1/CSF1R axis reprograms epithelial-to-mesenchymal phenotypes in inflammatory breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-14-02

Oct 22nd, 2018 - Inflammatory breast cancer (IBC) accounts for 2% of breast cancers but 10% of breast cancer-related deaths in the US. Clinical hallmarks of IBC are tumor cell emboli in lymphatic vessels and overexpression of E-cadherin, which promotes cell clustering. Given these hallmarks, IBC is thought to spread via collective invasion and cell clusters. However, we showed that IBC cells underwent epithelia...

Abstract P3-09-08: Overeating and breast cancer risk by pathologic subtypes: EpiGEICAM study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-09-08

Jun 28th, 2018 - Introduction: It has been reported that overeating may be the greatest avoidable cause of cancer in nonsmokers and obesity increases postmenopausal breast cancer (BC) risk. Calorie restriction reduces BC incidence in experimental animals, but the evidence in humans is more limited. This study analyzes the association between female BC risk and excessive or restricted calorie consumption in Spai...